The current COVID-19 global pandemic poses immense challenges to global health, largely
due to the difficulty to detect infection in the early stages of the disease, as well as the …

Many recent studies have reported the onset of a robust antibody response to SARS-CoV-2
infection and highlighted produced antibodies' specific qualitative and quantitative aspects …

The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) continues to spread
worldwide as a severe pandemic. Although its seroprevalence is highly variable among …

The ongoing pandemic of coronavirus disease 2019 (COVID‐19) has not only commenced
a global health emergency but also agitated various aspects of humanity. During this period …

Monoclonal antibodies (mAbs) had received emergency use authorization for mild-to-
moderate coronavirus disease 2019 (COVID-19) or for prophylaxis against COVID-19 …

Infection with SARS-CoV2 leads to COVID-19, the severity of which derives from the host's
immune response, especially the release of a storm of pro-inflammatory cytokines. This …

Global efforts to contain the coronavirus disease-2019 (COVID-19) include the development
of novel preventive vaccines and effective therapeutics. Passive antibody therapies using …

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has spread worldwide
causing a pandemic with millions of infected people and deaths. Currently, the scientific …

There is a desperate need for effective therapies and vaccines for SARS-CoV-2 to mitigate
the growing economic crisis that has ensued from societal lockdown. Vaccines are being …

We here describe the development and validation of IMMUNO-COV™, a high-throughput
clinical test to quantitatively measure SARS-CoV-2-neutralizing antibodies, the specific …